Exobiosphere to be First Commercial Customer of Outpost's Space Factories

Outpost Technologies Corporation announced on October 2, 2026, an agreement with space biotechnology firm Exobiosphere, making Exobiosphere the first announced customer for Outpost's newly unveiled "Space Factories" platform. This platform is designed for in-orbit manufacturing and research, with the capability to return products to Earth.

The agreement will see Exobiosphere utilize Outpost's CarryAll spacecraft to fly its microgravity drug discovery system, the Orbital High-Throughput System (OHTS). OHTS is an automated laboratory designed for disease research, drug screening, and sample return for further analysis on Earth. This marks the first commercial application of Outpost's "Space Factories," which offers standardized infrastructure for orbital research and manufacturing.

"Biopharmaceutical companies are beginning to treat microgravity as not just a research environment, but ready for scale manufacturing for therapeutics," said Jason Dunn, co-founder and CEO of Outpost. "That's exactly what we built Space Factories to serve: Exobiosphere brings the science, and we provide the standardized platform to fly it, operate it, and bring the results home."

Exobiosphere CEO Kyle Acierno highlighted that microgravity accelerates biological processes in ways not reproducible on Earth. With the International Space Station (ISS) nearing its planned decommissioning and commercial platforms emerging, Earth-return capability is becoming increasingly critical. Outpost's platform addresses this growing demand, enabling more frequent flights of OHTS modules and reliable return of results.

Outpost's CarryAll spacecraft are designed to return payloads from orbit, with capacities ranging from 200 kilograms to 10 metric tons. The system offers a scalable path from early orbital research to larger-volume manufacturing. The company's first orbital mission is planned for 2028.